HK Stock Market Move | ZYLOXTB (02190) rose nearly 7% during trading, with strong sales growth in core products. The company expects annual net profit to increase nearly 1.4 times year-on-year.

date
15:57 03/02/2026
avatar
GMT Eight
Guichuang Tongqiao (02190) rose nearly 7% during the trading day, as of the time of writing, it rose 5.65% to HK$25.04, with a turnover of HK$1788.45 million.
ZYLOXTB (02190) rose nearly 7% during trading hours, and at the time of writing, it was up 5.65% at 25.04 Hong Kong dollars, with a trading volume of 17.8845 million Hong Kong dollars. On the news front, ZYLOXTB recently announced a profit increase. It is expected that the net profit for the full year of 2025 will exceed 240 million yuan, an increase of approximately 139.4% compared to the same period last year; and the operating income will exceed 1.05 billion yuan, a year-on-year increase of about 34.6%. ZYLOXTB stated that the company's performance in 2025 is outstanding, mainly due to the strong growth in sales of core products, accelerated development of overseas business, and continuous optimization of operational efficiency. During the reporting period, the company's sales revenue of products such as Tongqiao Qilin blood flow guiding device, neurovascular guidewire, UltraFree drug-eluting PTA balloon dilatation catheter, and ZYLOX Swan venous intraluminal radiofrequency closure catheter all achieved rapid growth. In terms of international business, the company's overseas market sales revenue increased by over 100% year-on-year, with penetration rates in key markets such as Germany, France, and Italy continuing to rise. At the same time, the company's internationalization strategy achieved key breakthroughs, with comprehensive acceleration in overseas market expansion.